Kyorin Pharmaceutical Co (TSE:4569) 3-Year Book Growth Rate : 0.70% (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co 3-Year Book Growth Rate?

Kyorin Pharmaceutical Co's Book Value per Share for the quarter that ended in Dec. 2023 was 円2,208.84.

During the past 12 months, Kyorin Pharmaceutical Co's average Book Value per Share Growth Rate was -0.20% per year. During the past 3 years, the average Book Value per Share Growth Rate was 0.70% per year. During the past 10 years, the average Book Value per Share Growth Rate was 1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Kyorin Pharmaceutical Co was 8.30% per year. The lowest was -0.60% per year. And the median was 3.10% per year.

Competitive Comparison of Kyorin Pharmaceutical Co's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyorin Pharmaceutical Co's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's 3-Year Book Growth Rate falls into.

Kyorin Pharmaceutical Co 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Kyorin Pharmaceutical Co (TSE:4569) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Kyorin Pharmaceutical Co 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyorin Pharmaceutical Co (TSE:4569) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311

Website

https://www.kyorin-pharm.co.jp

Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines